Gyre Therapeutics (GYRE) Deferred Taxes (2023 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Deferred Taxes of -$738000.0 for Q1 2026, down 286.39% year-over-year from $395949.4 in Q1 2025, and down 748.28% quarter-over-quarter from -$87000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Deferred Taxes (2023 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Deferred Taxes for 4 consecutive years, with -$738000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Deferred Taxes fell 286.39% year-over-year to -$738000.0; the TTM figure through Mar 2026 stood at -$1.7 million (down 88.18% YoY), while the FY2025 annual figure was -$1.1 million, down 10.68% from the prior year.
- Deferred Taxes fell to -$738000.0 in Q1 2026 per GYRE's latest filing, from -$87000.0 in the prior quarter.
- Across five years, Deferred Taxes topped out at -$87000.0 in Q4 2025 and bottomed at -$738000.0 in Q1 2026.
- Historically, Deferred Taxes has averaged -$334083.3 across 4 years, with a median of -$306500.0 in 2024.
- Annual changes were most pronounced in 2025 — Deferred Taxes surged 85.3% — and 2026, when it sank 286.39%.
- Gyre Therapeutics' Deferred Taxes stood at -$403000.0 in 2023, then plunged by 46.9% to -$592000.0 in 2024, then soared by 85.3% to -$87000.0 in 2025, then slumped by 748.28% to -$738000.0 in 2026.
- Business Quant data shows GYRE's Deferred Taxes at -$738000.0 in Q1 2026, -$87000.0 in Q4 2025, and -$531000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -137,876.64 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.66 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | -1.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.43 Mn |
| Mar 31, 2026 | -738,000.00 |
| Dec 31, 2025 | -87,000.00 |
| Sep 30, 2025 | -531,000.00 |
| Jun 30, 2025 | -300,000.00 |
| Mar 31, 2025 | -191,000.00 |
| Dec 31, 2024 | -592,000.00 |
| Jun 30, 2024 | -97,000.00 |
| Mar 31, 2024 | -313,000.00 |
| Dec 31, 2023 | -403,000.00 |
| Sep 30, 2023 | -199,000.00 |
| Jun 30, 2023 | -230,000.00 |
| Mar 31, 2023 | -328,000.00 |